Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer

WANG Jie

doi:10.19401/j.cnki.1007-3639.2020.10.004

您当前的位置：

首页 >

文章列表页 >

Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer

更新时间：2026-01-27

- Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer
- China Oncology Vol. 30, Issue 10, Pages: 744-749(2020)
- 作者机构：
  
  国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院内科,北京,100021
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.10.004
  CLC：
- Published Online：11 November 2020，
  
  Published：11 November 2020
- 稿件说明：
移动端阅览
王　洁. 免疫检查点抑制剂在肺癌治疗应用中的挑战与方向[J]. 中国癌症杂志, 2020, 30(10): 744-749.

WANG Jie. Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer[J]. China Oncology, 2020, 30(10): 744-749.
王　洁. 免疫检查点抑制剂在肺癌治疗应用中的挑战与方向[J]. 中国癌症杂志, 2020, 30(10): 744-749. DOI： 10.19401/j.cnki.1007-3639.2020.10.004.

WANG Jie. Challenges and directions of immune checkpoint inhibitors in the treatment of lung cancer[J]. China Oncology, 2020, 30(10): 744-749. DOI： 10.19401/j.cnki.1007-3639.2020.10.004.

摘要

近年来，随着对免疫检查点研究的逐渐深入，免疫检查点抑制剂（immune checkpoint inhibitor，ICI）的研究也不断取得突破性进展，这使得肺癌的诊疗发生了革命性的变化。但是ICI在临床应用中仍存在获益人群有限、缺乏有效的生物标志物、治疗耐药及缺乏精准联合治疗方案等诸多问题和挑战。就程序性死亡［蛋白］配体-1（programmed death ligand-1，PD-L1）、肿瘤突变负荷（tumor mutation burden，TMB）作为常用ICI标志物的价值、局限性、其他潜在的新型生物标志物、免疫耐药的监测及应对、如何实现精准化免疫治疗以及新近取得的新药研发成果进行综述。

Abstract

In recent years

with the gradual in-depth research on immune checkpoints

breakthroughs have been made in the research of immune checkpoint inhibitors (ICI)

which has revolutionized the diagnosis and treatment of lung cancer. However

there are still many problems and challenges in the clinical application

such as the limited benefit population

the lack of effective biomarkers

treatment resistance

and the lack of precise combination treatment programs. This article summarized the value and limitations of programmed death ligand-1 (PD-L1) and tumor mutation burden (TMB) as common biomarkers of ICI

as well as other potential new biomarkers

the monitoring and responses to immunological resistance

how to achieve precise immunotherapy and the development results of new drugs.

关键词

Keywords

references

Views

2598

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of miR-503 targeting TLR4 on drug resistance to docetaxel in prostate cancer

Related Author

ZHOU Jian

ZHANG Chaoyang

SUN Wei

YANG Jun

ZHANG Zhichao

QI Xiaohong

Related Institution

Department of Urology, Wuhan Third Hospital

AI问答

⁰